Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

Rhea-AI Summary

Biora Therapeutics (Nasdaq: BIOR) announced that CEO Adi Mohanty will present the company's new 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting in Boston, October 28–29, 2024. The company has successfully reduced the device size from 000 to 00 while increasing payload capacity, aligning with strong patient and pharma collaborator preferences.

Mohanty emphasized the significance of this development, describing it as a revolutionary, needleless, liquid injection technology in a smaller, patient-friendly capsule. The presentation, titled 'Solving Drug Delivery Challenges with Ingestible Drug-Device Combinations,' is scheduled for October 28, 2024, at 3:30 PM Eastern Time in the Westin Boston Seaport.

The PODD meeting provides Biora Therapeutics an opportunity to update on their BioJet and NaviCap platforms and engage with existing pharma collaborators as they seek to expand these relationships.

Positive

• Successful reduction of BioJet device size from 000 to 00
• Increased payload capacity despite smaller device size
• Strong patient and pharma collaborator preference for 00-size device
• Opportunity to expand relationships with existing pharma collaborators

Negative

• None.

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company’s 00-size BioJet™ device at the 14^th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, taking place in Boston, October 28–29, 2024.

“As part of the development of our clinical-ready BioJet device, we were able to reduce its size from 000 to 00, while slightly increasing the payload capacity,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “Market research indicates a strong patient preference for a 00-size device, a preference that is shared by our pharma collaborators. We are excited about the progress we’ve made with this revolutionary, needleless, liquid injection technology in a smaller capsule that is readily accepted by patients. In addition to providing updates on our BioJet and NaviCap platforms, the PODD meeting also provides an opportunity to meet with a number of our existing pharma collaborators as we are in the process of expanding those relationships.”

Details of the presentation are as follows:

Presentation Title:	Solving Drug Delivery Challenges with Ingestible Drug-Device Combinations
Date & Time:	October 28, 2024, 3:30 – 3:45 PM Eastern Time
Track:	3A: Oral, Mucosal, Transdermal & Other Non-Injectable Technologies
Location:	Westin Boston Seaport, Grand Ballroom D/E, Concourse Level

PODD brings together professionals from pharma, biotech, and drug delivery industries to assess delivery needs and share information on the latest advances in drug delivery technologies that can potentially improve the delivery of various types of drugs, including proteins, peptides, mRNA therapies, oncology therapeutics, and small molecules.

About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech company developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free delivery.  

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.

Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model-based data projections for the BT-600 program, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390

Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com

FAQ

What is Biora Therapeutics' new BioJet device size announced for PODD 2024?

Biora Therapeutics announced a new 00-size BioJet™ device, reduced from the previous 000 size, which will be presented at the PODD meeting in October 2024.

When and where will Biora Therapeutics (BIOR) present its new BioJet device?

Biora Therapeutics will present its new 00-size BioJet device on October 28, 2024, at 3:30 PM Eastern Time during the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting in Boston.

What are the advantages of Biora Therapeutics' (BIOR) new 00-size BioJet device?

The new 00-size BioJet device offers increased payload capacity in a smaller capsule, aligns with patient and pharma collaborator preferences, and provides revolutionary, needleless, liquid injection technology that is more readily accepted by patients.

How does the PODD 2024 meeting benefit Biora Therapeutics (BIOR)?

The PODD 2024 meeting allows Biora Therapeutics to update on their BioJet and NaviCap platforms, meet with existing pharma collaborators, and explore opportunities to expand these relationships.